Climb Bio Strengthens Leadership with New CFO
Climb Bio, Inc. (NASDAQ: CLYM), a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, has announced the appointment of Susan Altschuller, Ph.D., MBA, as its new Chief Financial Officer. This strategic hire is set to enhance Climb Bio's leadership team and drive the company's financial strategies forward.
Bringing Extensive Experience to Climb Bio
Dr. Altschuller joins Climb Bio with over 20 years of rich experience in strategic and financial leadership within the biopharmaceutical sector. Her previous role as Chief Financial Officer at Cerevel Therapeutics involved navigating the company through its significant acquisition by AbbVie, a partnership valued at $8.7 billion. Additionally, her tenure at ImmunoGen was marked by support for the company's first commercial launch, highlighting her solid track record in financial execution and operational strategy.
A Proven Biopharmaceutical Leader
In her career, Dr. Altschuller has also held critical positions at Alexion, where she managed investor relations, along with enterprise finance roles at Bioverativ, which is known for its focus on hemophilia treatments. Starting her career as a consultant with the Frankel Group, she has built an impressive portfolio of leadership experiences that are sure to benefit Climb Bio and its mission.
Excitement for Future Developments
Commenting on her new position, Dr. Altschuller expressed enthusiasm for Climb Bio's vision. "I am inspired by the potential of Climb Bio's pipeline to make a significant impact on immune-mediated diseases," she stated. As the company advances its programs, which include budoprutug and CLYM116, her expertise will be pivotal in guiding the financial strategies that will empower Climb Bio as it reaches critical clinical milestones.
Advancing Clinical Pipelines
Climb Bio is currently focused on advancing budoprutug, an anti-CD19 monoclonal antibody that has demonstrated efficacy in depleting B-cells. This therapy has the potential to address various B-cell mediated diseases. Meanwhile, CLYM116 is an anti-APRIL monoclonal antibody being developed specifically for the treatment of IgA nephropathy, and the clinical development of these therapies aligns with Dr. Altschuller's leadership experience.
Equity Award for Dr. Altschuller
In connection with her appointment, Climb Bio has issued an inducement equity award to Dr. Altschuller. This award, established under the company's 2025 Inducement Plan, includes a non-statutory stock option to purchase 600,000 shares of Climb Bio common stock. The exercise price is set at the closing stock price as reported on her start date, reinforcing the company’s commitment to aligning her interests with those of its shareholders.
Commitment to Shareholder Value
Dr. Altschuller's stock option will vest over four years, ensuring her ongoing contribution to the company’s long-term success. She emphasized the importance of creating value for shareholders through the advancement of Climb Bio's promising therapeutic portfolio. This strategic focus on both innovation and fiscal responsibility sets the tone for the company’s trajectory in the biotechnology space.
About Climb Bio, Inc.
Climb Bio is dedicated to developing therapeutics that address severe immune-mediated diseases. Their innovative pipeline, featuring budoprutug and CLYM116, underscores a commitment to offering patients effective treatment options. As the company evolves, it remains focused on patient-centric solutions and scientific advancements in the field of immunology.
Contact and Further Information
For more details or inquiries, interested parties can contact Carlo Tanzi, Ph.D., at Kendall Investor Relations via email at catanzi@kendallir.com. Stay updated on Climb Bio's progress and initiatives as it continues to expand its role in the biopharmaceutical market.
Frequently Asked Questions
Who is the new Chief Financial Officer at Climb Bio?
Susan Altschuller, Ph.D., MBA, has been appointed as the new Chief Financial Officer at Climb Bio.
What experience does Dr. Altschuller bring to Climb Bio?
Dr. Altschuller has over 20 years of experience in financial leadership within the biopharmaceutical industry, including key roles at Cerevel Therapeutics and ImmunoGen.
What are Climb Bio's primary therapeutic focuses?
Climb Bio focuses on developing treatments for immune-mediated diseases, with pipelines that include budoprutug and CLYM116.
How will Dr. Altschuller impact Climb Bio?
Her extensive experience in strategic financial management is expected to significantly contribute to Climb Bio's clinical advancements and financial strategies.
What is the significance of the inducement equity award for Dr. Altschuller?
The inducement equity award aligns Dr. Altschuller’s incentives with the company's performance, ensuring her commitment to enhancing shareholder value.
